Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.

Diane Ito,Chaoling Feng,Christine Fu,Chong Kim,James Wu,Josh Epstein,Julia T Snider,Adam S DuVall

Expert review of pharmacoeconomics & outcomes research（2023）

引用 0|浏览1

暂无评分

摘要

During the period ending in 2020, patients relapsed frequently, incurring high HRU and costs across LoTs. More effective treatments with long-lasting remissions in R/R MCL may reduce healthcare burden.

查看译文

关键词

Bruton tyrosine kinase inhibitor, BTKi, costs, economic burden, healthcare resource utilization, mantle cell lymphoma, MCL, relapsed or refractory, treatment patterns

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要